Company principal scientist David Flowers, PhD, will present a poster titled, "A Computational Semimechanistic Pharmacology Model of ATG-101, a PD-L1/4-1BB Bispecific Antibody for Treatment of Solid Tumors." The work describes the company's collaboration with Antengene on the development of a systems pharmacology model for understanding the treatment's tumor-killing mechanism.

A second poster presentation describes results of the company's collaboration with Genmab and is titled, "Dose Selection for DuoBody-PD-L1×4-1BB (GEN1046) Using a Semimechanistic Pharmacokinetics/Pharmacodynamics Model That Leverages Preclinical and Clinical Data."

The SITC meeting will be held November 10-14, 2021.

ImmunoGenesis data to be presented at SITC 2021
Data from ImmunoGenesis will be presented at the Society for Immunotherapy of Cancer (SITC) annual meeting scheduled for November 10-14 in Washington,...

Immatics to highlight ACTengine program updates at SITC
Immatics plans to offer an update on its ACTengine IMA203 trial at the upcoming Society for Immunotherapy of Cancer (SITC) 2021 annual meeting in Washington,...

Incyte to showcase oncology portfolio at SITC
Incyte plans to highlight clinical study data for its oncology portfolio at the upcoming Society for Immunotherapy of Cancer (SITC) 2021 annual meeting...

Gamida highlights poster presentations at SITC 2021
Cell therapy firm Gamida Cell is directing attention to two poster presentations at the annual meeting of the Society for Immunotherapy of Cancer (SITC)...